Home
Publication
Commentaries
Role of hFlt3L in the development of myeloid and dendritic cells in genO‑BRGSF‑HIS mice

Role of hFlt3L in the development of myeloid and dendritic cells in genO‑BRGSF‑HIS mice

10 min read
October 22, 2025

SUMMARY

• The genO-BRGSF-HIS mouse model is a translatable mouse model containing a functional human immune system following reconstitution with human CD34+ hematopoietic stem cells, with no side effects.

• Treatment with hFlt3L provided by Bio X Cell enhances the development of myeloid and dendritic cells in the genO-BRGSF-HIS mouse model.

• The genO-BRGSF-HIS model boosted with Bio X Cell's hFlt3L enables efficacy and safety testing of new therapeutics.

‍

Related products

Catalogue product

genO‑BRGSF‑HIS

genO‑BRGSF‑HIS mice possess the most functional reconstituted human immune system currently on the market and are highly relevant for translational research.

Customized product

No items found.
Other commentaries
New CD4-specific minibodies to predict cancer treatment outcomes

CD4 for cancer treatment outcomes

5 min read
-
Oct 2024
Development of a new antibody-drug conjugate against CD71, INA03, for the treatment of leukemia

TFRC for anti-cancer therapies

8 min read
-
Jul 2024
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

VISTA - safety and PK profiling

8 min read
-
Apr 2024
BRGSF-HIS: genOway’s mouse model to evaluate the pathogenesis of Staphylococcus aureus Panton-Valentine leukocidin in acute implant-associated osteomyelitis

BRGSF-HIS as model for acute implant-associated osteomyelitis

10 min read
-
Apr 2024
Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized genO-hCD47/hSIRPα mouse and genO-MC38-hPD-L1-hCD47-LZ cell line

Targeting the human CD47/SIRPα axis

10 min read
-
Mar 2024
Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized genO-BRGSF-HIS preclinical model

CRS in genO-BRGSF-HIS

7 min read
-
Feb 2024
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Humanized VISTA mouse & Pharmacokinetics

10 min read
-
Dec 2023
Targeting myeloid cells in the tumor microenvironment in BRGSF-HIS mice

Myeloid compartment in BRGSF-HIS

7 min read
-
Dec 2023
Assessing T-cell engagers efficacy in vivo: Versatility of BRGSF-HIS mice

Assess T-cell engager in BRGSF-HIS

3 min read
-
Oct 2023
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

9 min read
-
Jun 2023
Expression of druggable myeloid targets in the BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

3 min read
-
Mar 2023
An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Humanized HSA/hFcRn mouse

3 min read
-
Nov 2022
Functional human myeloid compartment in BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

4 min read
-
Nov 2022
A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

10 min read
-
Jul 2022
Assessing T-cell engagers in vivo: How BRGSF-HIS mice can help

Assess T-cell engager in BRGSF-HIS

6 min read
-
Jun 2022
Homeostasis of monocytes and lung interstitial macrophages is regulated by collagen domain-binding receptor LAIR1 in vivo

Myeloid compartment in BRGSF-HIS

6 min read
-
Jun 2022
Challenging the predictability of preclinical models for assessment of T-cell engagers

Assess T-cell engager in BRGSF-HIS

5 min read
-
May 2022
Targeting tumor-associated myeloid cells: The new grail in immuno-oncology?

Myeloid compartment in immuno-oncology

3 min read
-
Apr 2022
Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

T-cell engager CD3

3 min read
-
Mar 2022
An alternative approach to immunotherapy: A bispecific agonist

Humanized PD-1 & GITR mouse

4 min read
-
Mar 2022
Relevant preclinical models to test T-cell engagers: The case of CD28

T-cell engager

5 min read
-
Mar 2022
Immunocompromised human serum albumin/human neonatal Fc receptor mouse model: A new xenograft model for efficacy studies of immunotherapies

Therapeutic efficacy and pharmacokinetics

8 min read
-
Jan 2022
Immunotherapy efficacy assessment and metastases studies: tHIS model is highly permissive to engraftment

Engraftments in BRGSF-HIS

8 min read
-
Nov 2021
NOTUM as alternative therapeutic approach to prevent clonal fixation and mutant expansion in patients predisposed to colorectal cancer

Customized mouse model

3 min read
-
Nov 2021
A human-specific modifier of cortical connectivity and circuit function

Customized mouse model

3 min read
-
Nov 2021
Predictive in vivo evaluation of immunotherapy efficacy: tHIS is a reliable model

PDX in BRGSF-HIS

6 min read
-
Nov 2021
Cytokine release syndrome (CRS)

Assess T-cell engager in BRGSF-HIS

5 min read
-
Sep 2021
The importance of genetic design when choosing your preclinical model - A Case Study on GLP-1R

Physiological relevancy in preclinical models

4 min read
-
Sep 2021
Deciphering high-dose IL-2 toxicity in reconstituted HIS mice

Immunotherapy in BRGSF-HIS

6 min read
-
Aug 2021
Tumor grafts in preclinical research: Models, models, overall, who is the fittest of them all?

Tumor-graft models

5 min read
-
Aug 2021
New doors to potential novel treatments for obesity

Customized mouse model

3 min read
-
Jun 2021
Uncoupling efficacy from toxicity: a case study on MEDI5752

Bispecific antibodies

5 min read
-
Apr 2021
Uncoupling toxicity from therapeutic efficacy: a case study on ATOR-1015

Bispecific antibodies

5 min read
-
Apr 2021
Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies

Assess toxicity with ICP

3 min read
-
Apr 2021
A novel preclinical and translational humanized CD3ε model to study the efficacy of T-cell engagers

T-cell engager

8 min read
-
Feb 2021
Define “humanized”: two mouse models helping produce cancer immunotherapies

Humanized mouse models

4 min read
-
Nov 2020
HSA/hFcRn, a powerful model for your PK/PD studies

Immuno-oncolology models

6 min read
-
Jul 2020
Part 4: Humanized immune checkpoint mouse models for immuno-oncology studies

Immuno-oncolology models

15 min read
-
May 2020
A Knockin C3-reporter mouse model represents a valuable tool to monitor C3 levels, a biomarker of inflamed versus uninflamed tissues

Customized mouse model

3 min read
-
Apr 2020
Part 3: BRGSF-HIS, a new human immune system mouse model for immuno-oncology studies

Immuno-oncolology models

6 min read
-
Apr 2020
Syngeneic mouse models

Customized mouse model

3 min read
-
Apr 2020
Part 2: BRGSF, a new immunodeficient model for immuno-oncology studies

Immuno-oncolology models

6 min read
-
Mar 2020
HSC-derived cell fate tracking

Customized mouse model

3 min read
-
Mar 2020
A VISTA on naive T cell fate

Humanized ICP mouse

3 min read
-
Feb 2020
Part 1:  Toward a better effective preclinical model in immuno-oncology

Immuno-oncolology models

10 min read
-
Jan 2020
A finely tuned crosstalk between enteric neurons and muscularis macrophages: evidence from a conditional Knockout mouse model developed by genOway

Customized mouse model

3 min read
-
Jan 2020
A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies

Humanized ICP in immuno-oncology

3 min read
-
Oct 2019
6 good reasons to employ our repository Knockout mouse models in your in vivo studies

Eucomm conditional Knockouts

6 min read
-
Aug 2019
Immune checkpoint inhibitors: A strategy to tackle cancer?

Immuno-oncology models (ICP)

3 min read
-
Jul 2019
Show all commentaries
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe

Mouse
Immuno-Oncology